Apogee Sets August 11 Vote on $10.9B AbbVie Buyout at $135.11/Share
APGE has more than doubled off its 52-week low of $34.34.
Summary
Apogee's definitive proxy sets an August 11 stockholder vote on AbbVie's $10.9B all-cash acquisition at $135.11 per share, a 53% premium. The filing details the negotiation process, fairness opinions, and management projections, with closing expected in Q3 2026 pending regulatory approvals.
Key Events · M&A and Partnerships · APGE
-
Merger Vote Set for August 11
Stockholders of record as of July 10 will vote on the $135.11 per share all-cash acquisition by AbbVie, with the meeting to be held virtually.
-
Deal Price Represents 53% Premium
The $135.11 per share offer is a 53% premium to Apogee's closing price on June 17, 2026, and a 63% premium to the 30-day VWAP, following negotiations that raised AbbVie's initial $124 bid.
-
Fairness Opinions and Projections Disclosed
Goldman Sachs and Jefferies provided fairness opinions, relying on management projections that show zumilokibart peak sales of $9.3B in 2038, with a discounted cash flow analysis implying a per-share value of $98.90–$119.20.
-
Regulatory Approvals Underway
HSR filing was made on July 6, with the waiting period expiring August 5; notifications were also filed in Germany and Austria, and pre-notification discussions began in Australia.
Analysis · APGE · Life Sciences
The definitive proxy locks in the August 11 stockholder vote on AbbVie's $135.11 per share all-cash acquisition. After AbbVie's initial $124 offer, the board secured a 9% bump to $135.11—a 53% premium to the undisturbed price—and no other bidder emerged despite outreach to four other parties. The deal is backed by fairness opinions from Goldman Sachs and Jefferies, and the proxy details management's projections showing zumilokibart peak sales of $9.3B in 2038. With the HSR waiting period set to expire August 5 and key stockholders already committed to vote in favor, the path to closing looks clear, though the $381M mutual termination fees underscore the stakes if antitrust issues arise.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 41.1% of the 372 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, APGE was trading at $133.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.1B. The 52-week trading range was $34.34 to $133.88. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.